Food and Beverage

Return to Article

Forest Labs Antibiotic Meets Pneumonia Study Goals

The Associated Press

NEW YORK (AP) — Drug developer Forest Laboratories Inc. said Friday its developing antibiotic ceftaroline met key study goals in treating hospital-acquired pneumonia.

In two late-stage, or Phase III clinical trials, the drug had a higher cure rate than the antibiotic ceftriaxone in patients with moderate to severe forms of the condition.

The company expects to ask for Food and Drug Administration approval near the end of the year.

Shares of Forest Laboratories rose 9 cents to $24.29 in afternoon trading.